Pfizer Total Non-Operating Income/Expense 2012-2026 | PFE
Pfizer annual/quarterly total non-operating income/expense history and growth rate from 2012 to 2026. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Pfizer total non-operating income/expense for the quarter ending March 31, 2026 was $-0.861B, a 9.65% decline year-over-year.
- Pfizer total non-operating income/expense for the twelve months ending March 31, 2026 was $-6.631B, a 42.27% increase year-over-year.
- Pfizer annual total non-operating income/expense for 2025 was $-6.724B, a 53.24% increase from 2024.
- Pfizer annual total non-operating income/expense for 2024 was $-4.388B, a 1876.58% increase from 2023.
- Pfizer annual total non-operating income/expense for 2023 was $-0.222B, a 79.1% decline from 2022.
|
Pfizer Annual Total Non-Operating Income/Expense (Millions of US $) |
|
|---|---|
| 2025 | $-6,724 |
| 2024 | $-4,388 |
| 2023 | $-222 |
| 2022 | $-1,062 |
| 2021 | $4,878 |
| 2020 | $-1,213 |
| 2019 | $4,610 |
| 2018 | $-2,077 |
| 2017 | $-1,416 |
| 2016 | $-3,794 |
| 2015 | $-2,860 |
| 2014 | $-1,009 |
| 2013 | $532 |
| 2012 | $-4,022 |
| 2011 | $-2,486 |
|
Pfizer Quarterly Total Non-Operating Income/Expense (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-861 |
| 2025-12-31 | $-4,514 |
| 2025-09-30 | $-517 |
| 2025-06-30 | $-739 |
| 2025-03-31 | $-953 |
| 2024-12-31 | $-2,358 |
| 2024-09-30 | $-243 |
| 2024-06-30 | $-1,107 |
| 2024-03-31 | $-680 |
| 2023-12-31 | $159 |
| 2023-09-30 | $-181 |
| 2023-06-30 | $75 |
| 2023-03-31 | $-275 |
| 2022-12-31 | $1 |
| 2022-09-30 | $59 |
| 2022-06-30 | $-772 |
| 2022-03-31 | $-350 |
| 2021-12-31 | $835 |
| 2021-09-30 | $1,696 |
| 2021-06-30 | $1,343 |
| 2021-03-31 | $1,004 |
| 2020-12-31 | $-106 |
| 2020-09-30 | $-1,878 |
| 2020-06-30 | $955 |
| 2020-03-31 | $-184 |
| 2019-12-31 | $-2,940 |
| 2019-09-30 | $7,768 |
| 2019-06-30 | $-126 |
| 2019-03-31 | $-92 |
| 2018-12-31 | $-3,220 |
| 2018-09-30 | $414 |
| 2018-06-30 | $551 |
| 2018-03-31 | $178 |
| 2017-12-31 | $-1,352 |
| 2017-09-30 | $-79 |
| 2017-06-30 | $75 |
| 2017-03-31 | $-60 |
| 2016-12-31 | $-979 |
| 2016-09-30 | $-1,417 |
| 2016-06-30 | $-1,068 |
| 2016-03-31 | $-330 |
| 2015-12-31 | $-2,190 |
| 2015-09-30 | $-661 |
| 2015-06-30 | $-55 |
| 2015-03-31 | $46 |
| 2014-12-31 | $-345 |
| 2014-09-30 | $-94 |
| 2014-06-30 | $53 |
| 2014-03-31 | $-623 |
| 2013-12-31 | $18 |
| 2013-09-30 | $-411 |
| 2013-06-30 | $1,070 |
| 2013-03-31 | $-145 |
| 2012-12-31 | $-739 |
| 2012-09-30 | $-937 |
| 2012-06-30 | $-688 |
| 2012-03-31 | $-1,658 |
| 2011-12-31 | $-689 |
| 2011-09-30 | $-547 |
| 2011-06-30 | $-423 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |